Brokerages Set Vor Biopharma Inc. (NASDAQ:VOR) Price Target at $43.38

Vor Biopharma Inc. (NASDAQ:VOR) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $43.3750.

A number of research analysts recently weighed in on VOR shares. Wall Street Zen upgraded shares of Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Wedbush increased their target price on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th.

Vor Biopharma Trading Down 7.4%

Shares of Vor Biopharma stock opened at $23.24 on Thursday. The business’s 50 day moving average price is $21.64 and its 200 day moving average price is $17.34. Vor Biopharma has a one year low of $6.50 and a one year high of $49.95.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of VOR. Bank of America Corp DE increased its stake in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after purchasing an additional 4,144 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Vor Biopharma during the 3rd quarter valued at approximately $230,000. BNP Paribas Financial Markets increased its stake in Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in Vor Biopharma during the third quarter worth $304,000. Finally, Engineers Gate Manager LP grew its holdings in Vor Biopharma by 37.5% in the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after purchasing an additional 10,071 shares during the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).